USPTO Grants Patent for RSV Inhibitors
Summary
The USPTO has granted a new patent (US12582661B2) to SHANGHAI ARK BIOPHARMACEUTICAL CO., LTD. for a class of respiratory syncytial virus (RSV) inhibitors. The patent, effective March 24, 2026, covers compounds with potential advantages in activity and in vivo exposure compared to existing treatments.
What changed
The United States Patent and Trademark Office (USPTO) has granted patent US12582661B2 to SHANGHAI ARK BIOPHARMACEUTICAL CO., LTD. This patent, effective March 24, 2026, covers the synthesis and application of a class of respiratory syncytial virus (RSV) inhibitors. The disclosed compounds, described by formula I, are claimed to offer superior activity and higher in vivo exposure compared to existing inhibitors.
This patent grant signifies a new intellectual property right for the assignee in the field of antiviral therapeutics. While patent grants are non-binding regulatory notices, they are crucial for understanding the competitive landscape and potential future market entrants in the pharmaceutical sector. Compliance officers in related fields should note this development as it pertains to innovation and potential market exclusivity for RSV treatments.
Archived snapshot
Mar 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Synthesis and application of class of respiratory syncytial virus inhibitors
Grant US12582661B2 Kind: B2 Mar 24, 2026
Assignee
SHANGHAI ARK BIOPHARMACEUTICAL CO., LTD.
Inventors
Cheng Peng, Xiashi Lv, Mengfei Qian, Wei Yin, Chaojun Gong, Jian Han, Wei Shen, Danbin Li, Gang Zou, Haiqing Yuan, Zhen Jim Wu
Abstract
The present disclosure provides the synthesis and application of respiratory syncytial virus inhibitor, being a compound of formula I or a pharmaceutically acceptable salt, ester, isomer, solvate, prodrug or isotope label thereof.
Compared with the existing inhibitors, the compounds of formula I have the advantages of superior activity and higher exposure in vivo.
CPC Classifications
A61K 31/554 A61P 11/00 A61P 31/12 A61P 31/14 C07D 417/04 C07D 417/14
Filing Date
2021-01-21
Application No.
17790987
Claims
11
Named provisions
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.